|
Jan 15
|
Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why
|
|
Jan 12
|
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
|
|
Jan 11
|
Aclaris (ACRS) Down 21% on Mixed Results From Eczema Study
|
|
Jan 11
|
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
|
|
Jan 11
|
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
|
|
Jan 11
|
The Zacks Analyst Blog Highlights DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics
|
|
Jan 10
|
Sarepta Rebounded. Its Gene Therapy Is Back on Course.
|
|
Jan 10
|
GSK to Buy Private Biotech, Strengthen Respiratory Pipeline
|
|
Jan 10
|
Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?
|
|
Jan 9
|
Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results
|
|
Jan 9
|
Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last?
|
|
Jan 9
|
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
|
|
Jan 5
|
Allogene (ALLO) Down 20% on Strategic Changes in Pipeline
|
|
Jan 5
|
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
|
|
Jan 4
|
Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo
|
|
Jan 4
|
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.54%: Here's is How to Trade
|
|
Jan 3
|
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
|
|
Jan 3
|
Best Momentum Stocks to Buy for January 3rd
|
|
Jan 2
|
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 29
|
Sarepta (SRPT): Strong Industry, Solid Earnings Estimate Revisions
|